SIGNATOPE
SIGNATOPE GmbH is a biotech company founded in 2016 in Reutlingen, Germany, specializing in developing innovative protein-assays and analytical services for pharmaceutical and chemical industries. They focus on creating assays for detecting and quantifying biomarkers related to organ damage and drug interactions, utilizing advanced mass spectrometry and immunoassay technologies. The company is committed to advancing biomarker research and improving drug safety and efficacy.
Industries
Nr. of Employees
small (1-50)
Products
Terminal-sequence-recognizing antibody collection (~6,000 protein targets)
A reagent collection of monoclonal antibodies targeting tetramer peptide termini adjacent to protease cleavage sites, enabling capture of peptides from thousands of proteins for targeted mass spectrometric assays.
Targeted immunoaffinity LC-MS/MS assay panels (examples: CYPs and drug transporters)
Preconfigured targeted mass spectrometry-based immunoassay panels for direct quantification of drug-metabolizing enzymes and transport proteins in tissues and cell lysates.
SIGNATOX
Translational safety biomarkers test system for quantifying identical protein biomarkers for drug-induced kidney and liver injury across multiple species in preclinical and clinical phases.
SIGNATOX DILI Panel
A cutting-edge assay family designed to quantify clinically relevant biomarkers for drug-induced liver injury (DILI) safety, focusing on MCSF1R, OPN, HMGB1, GLDH, ccK18, and K18.
Full DIKI panel
Comprehensive drug-induced kidney injury panel covering VCAM1, MMP3, and HMGB1 for urine samples.
MPh26
Assay panel covering AMPB, CST3, OPN, and RBP4 for urine samples.
Terminal-sequence-recognizing antibody collection (~6,000 protein targets)
A reagent collection of monoclonal antibodies targeting tetramer peptide termini adjacent to protease cleavage sites, enabling capture of peptides from thousands of proteins for targeted mass spectrometric assays.
Targeted immunoaffinity LC-MS/MS assay panels (examples: CYPs and drug transporters)
Preconfigured targeted mass spectrometry-based immunoassay panels for direct quantification of drug-metabolizing enzymes and transport proteins in tissues and cell lysates.
SIGNATOX
Translational safety biomarkers test system for quantifying identical protein biomarkers for drug-induced kidney and liver injury across multiple species in preclinical and clinical phases.
SIGNATOX DILI Panel
A cutting-edge assay family designed to quantify clinically relevant biomarkers for drug-induced liver injury (DILI) safety, focusing on MCSF1R, OPN, HMGB1, GLDH, ccK18, and K18.
Full DIKI panel
Comprehensive drug-induced kidney injury panel covering VCAM1, MMP3, and HMGB1 for urine samples.
MPh26
Assay panel covering AMPB, CST3, OPN, and RBP4 for urine samples.
Services
Development, optimization and analytical validation of targeted immunoaffinity–mass spectrometry assays for detection and quantification of protein biomarkers in blood, urine and tissue.
In-silico and reagent matching service using Uniprot IDs or FASTA sequences to identify antibodies that bind conserved tetramer peptide termini, with a stated response turnaround.
Analytical laboratory services to measure and report biomarker concentrations using targeted proteomics workflows for industry and consortium projects.
Development, optimization and analytical validation of targeted immunoaffinity–mass spectrometry assays for detection and quantification of protein biomarkers in blood, urine and tissue.
In-silico and reagent matching service using Uniprot IDs or FASTA sequences to identify antibodies that bind conserved tetramer peptide termini, with a stated response turnaround.
Analytical laboratory services to measure and report biomarker concentrations using targeted proteomics workflows for industry and consortium projects.
Expertise Areas
- Targeted mass spectrometry-based immunoassays
- Biomarker assay development and validation
- Immunoaffinity enrichment for proteomics
- Cross-species biomarker assay design
Key Technologies
- Immunoaffinity enrichment
- LC-MS/MS
- Immuno-MRM
- Immuno‑MALDI
News & Updates
Signatope's CEO Oliver Pötz and Senior Scientist Helen Hammer will present at the 2nd ISSX 2-Day Workshop on Quantitative LC-MS/MS Proteomics in June 2024 in Sheffield, UK.
Signatope will exhibit at the Society of Toxicology (SOT) Conference 2024 in Salt Lake City, Utah, from March 10-14, 2024, showcasing advancements in toxicology research.
SIGNATOPE was recognized as one of Germany's fastest-growing technology companies, ranking 42nd in the Deloitte Technology Fast 50 with a focus on innovative analysis strategies for protein biomarkers.
Signatope is part of the TransBioLine consortium, a European project to develop and qualify new safety biomarkers for various organs, funded by the EU and pharmaceutical companies.
Signatope's biomarker test system for specific and reliable biomarker detection in various biological samples was awarded the Dr. Rudolph-Eberle-Preis 2019, the Innovation Award of Baden-Württemberg.
Signatope's CEO Oliver Pötz and Senior Scientist Helen Hammer will present at the 2nd ISSX 2-Day Workshop on Quantitative LC-MS/MS Proteomics in June 2024 in Sheffield, UK.
Signatope will exhibit at the Society of Toxicology (SOT) Conference 2024 in Salt Lake City, Utah, from March 10-14, 2024, showcasing advancements in toxicology research.
SIGNATOPE was recognized as one of Germany's fastest-growing technology companies, ranking 42nd in the Deloitte Technology Fast 50 with a focus on innovative analysis strategies for protein biomarkers.
Signatope is part of the TransBioLine consortium, a European project to develop and qualify new safety biomarkers for various organs, funded by the EU and pharmaceutical companies.
Signatope's biomarker test system for specific and reliable biomarker detection in various biological samples was awarded the Dr. Rudolph-Eberle-Preis 2019, the Innovation Award of Baden-Württemberg.